Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CID-078 in Advanced Solid Tumors
NCT06577987Phase 1Active, not recruiting
- Sponsor
- Circle Pharma
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CID-078 in solid tumor, triple-negative breast cancer (TNBC) and small cell lung cancer (SCLC), sponsored by Circle Pharma. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Incidence of Treatment Related Adverse Events and 6 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
CID-078
03
Conditions
solid tumortriple-negative breast cancer (TNBC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06577987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577987.